KIF1A.ORG Community, What if KIF1A treatment already existed? It could be on the shelves of your local pharmacy, or a drug created for a related disease like Parkinson’s or epilepsy. Are there FDA-approved treatments for other conditions that could bring relief to KAND patients living with progressive spasticity, uncontrolled seizures or painful neuropathy? We won’t…
Read More
#ScienceSaturday posts share relevant and exciting scientific news with the KAND community. This project is a collaboration between KIF1A.ORG’s Research Engagement Team Leader Alejandro Doval, President Kathryn Atchley, Science Communication Associate Aileen Lam and Chief Science Officer Dr. Dominique Lessard. Send news suggestions to our team at impact@kif1a.org.
Read More
KIF1A.ORG Community, Today we’re highlighting the exciting work we’re doing with Albany Molecular Research Inc. (AMRI) to support KIF1A.ORG’s therapeutic development efforts. This project was made possible by a Rising Tides grant awarded by The Child Neurology Foundation to support organizations during the COVID-19 pandemic.
Read More#ScienceSaturday posts share relevant and exciting scientific news with the KAND community. This project is a collaboration between KIF1A.ORG’s Research Engagement Team Leader Alejandro Doval, President Kathryn Atchley and Chief Science Officer Dr. Dominique Lessard. Send news suggestions to our team at impact@kif1a.org.
Read More
By Luke Rosen Susannah does not wear pajamas to bed, she wears battle gear. After her bath is finished, teeth brushed, stories read and songs sang, it is time for the grueling marathon that is Susannah’s rare, nocturnal epilepsy. Her nine-year-old brother, Nat, flies into the bedroom like Superman and hugs her tight. “Night Shasha!”…
Read More
KIF1A.ORG Community, We are thrilled to introduce you to two new staff members: Charlotte Klinepeter, Administrative Manager, and Aileen Lam, Science Communication Associate! Charlotte and Aileen bring valuable strengths and experiences to the organization and expand our capacity to accelerate our mission.
Read More#ScienceSaturday posts share relevant and exciting scientific news with the KAND community. This project is a collaboration between KIF1A.ORG’s Research Engagement Team Leader Alejandro Doval, President Kathryn Atchley and Chief Science Officer Dr. Dominique Lessard. Send news suggestions to our team at impact@kif1a.org.
Read More#ScienceSaturday posts share relevant and exciting scientific news with the KAND community. This project is a collaboration between KIF1A.ORG’s Research Engagement Team Leader Alejandro Doval, President Kathryn Atchley and Chief Science Officer Dr. Dominique Lessard. Send news suggestions to our team at impact@kif1a.org.
Read More
KIF1A.ORG Community, We’re excited to introduce one of our newest partners, the Bařinka Lab at Institute of Biotechnology of the Czech Academy of Sciences in the Czech Republic! Our partnership will enable the Bařinka Lab to collaborate with HNF Pharma Inc. and The Jackson Laboratory to study a potential drug therapy for KIF1A Associated Neurological…
Read More#ScienceSaturday posts share relevant and exciting scientific news with the KAND community. This project is a collaboration between KIF1A.ORG’s Research Engagement Team Leader Alejandro Doval, President Kathryn Atchley and Chief Science Officer Dr. Dominique Lessard. Send news suggestions to our team at impact@kif1a.org.
Read More
KIF1A.ORG Community, KIF1A.ORG is excited to share a series of announcements about recently funded projects powered to rapidly discover and develop treatments for people affected by KAND. First up: The McKenney Lab at University of California, Davis. Led by Richard McKenney, PhD, the McKenney Lab has long collaborated with KIF1A.ORG, and leads the field in…
Read More